RU2011125971A - Способ лечения болезни паркинсона - Google Patents
Способ лечения болезни паркинсона Download PDFInfo
- Publication number
- RU2011125971A RU2011125971A RU2011125971/15A RU2011125971A RU2011125971A RU 2011125971 A RU2011125971 A RU 2011125971A RU 2011125971/15 A RU2011125971/15 A RU 2011125971/15A RU 2011125971 A RU2011125971 A RU 2011125971A RU 2011125971 A RU2011125971 A RU 2011125971A
- Authority
- RU
- Russia
- Prior art keywords
- bacteriophage
- antibody
- filamentous
- binds
- protein
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title claims abstract 6
- 238000000034 method Methods 0.000 title claims 12
- 241000724791 Filamentous phage Species 0.000 claims abstract 25
- 241001515965 unidentified phage Species 0.000 claims abstract 24
- 239000000203 mixture Substances 0.000 claims abstract 15
- 102000004127 Cytokines Human genes 0.000 claims abstract 11
- 108090000695 Cytokines Proteins 0.000 claims abstract 11
- 239000000427 antigen Substances 0.000 claims abstract 10
- 102000036639 antigens Human genes 0.000 claims abstract 10
- 108091007433 antigens Proteins 0.000 claims abstract 10
- 230000000770 proinflammatory effect Effects 0.000 claims abstract 10
- 210000004962 mammalian cell Anatomy 0.000 claims abstract 8
- 101710120037 Toxin CcdB Proteins 0.000 claims abstract 6
- 102000004169 proteins and genes Human genes 0.000 claims abstract 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract 6
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims abstract 5
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims abstract 5
- 102000003802 alpha-Synuclein Human genes 0.000 claims abstract 5
- 108090000185 alpha-Synuclein Proteins 0.000 claims abstract 5
- 241001524679 Escherichia virus M13 Species 0.000 claims abstract 3
- 241000702371 Enterobacteria phage f1 Species 0.000 claims abstract 2
- 241000702374 Enterobacteria phage fd Species 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11744608P | 2008-11-24 | 2008-11-24 | |
| US61/117,446 | 2008-11-24 | ||
| PCT/US2009/065659 WO2010060073A2 (en) | 2008-11-24 | 2009-11-24 | Method for treating parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011125971A true RU2011125971A (ru) | 2012-12-27 |
Family
ID=41572327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011125971/15A RU2011125971A (ru) | 2008-11-24 | 2009-11-24 | Способ лечения болезни паркинсона |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20110286970A1 (enExample) |
| EP (2) | EP2478911A1 (enExample) |
| JP (1) | JP2012509672A (enExample) |
| KR (1) | KR20110091778A (enExample) |
| CN (1) | CN102223887B (enExample) |
| AU (1) | AU2009316326A1 (enExample) |
| BR (1) | BRPI0921557A2 (enExample) |
| CA (1) | CA2744339A1 (enExample) |
| CO (1) | CO6390112A2 (enExample) |
| IL (1) | IL213120A0 (enExample) |
| MX (1) | MX2011005430A (enExample) |
| NZ (1) | NZ592928A (enExample) |
| RU (1) | RU2011125971A (enExample) |
| SG (1) | SG171791A1 (enExample) |
| WO (1) | WO2010060073A2 (enExample) |
| ZA (1) | ZA201104701B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE555128T1 (de) | 2006-11-30 | 2012-05-15 | Res Dev Foundation | Verbesserte immunglobulin-bibliotheken |
| WO2009143470A1 (en) * | 2008-05-22 | 2009-11-26 | Ramot At Tel Aviv University Ltd. | Method for treating disease characterized by plaque |
| CA2829223A1 (en) | 2011-03-11 | 2012-09-20 | Beka Solomon | Method for treating neurodegenerative tauopathy |
| EP2736522A1 (en) | 2011-07-27 | 2014-06-04 | Neurophage Pharmaceuticals, Inc. | Process for the production of filamentous bacteriophage |
| CN104093414A (zh) * | 2011-11-29 | 2014-10-08 | 神经噬菌体制药股份有限公司 | 噬菌体的p3作为淀粉样蛋白结合剂的用途 |
| TWI613212B (zh) | 2012-10-02 | 2018-02-01 | 波克萊拉生物科技股份有限公司 | 作爲澱粉樣蛋白結合劑之ｇ３ｐ融合蛋白 |
| AU2014274253B2 (en) | 2013-05-28 | 2018-06-14 | Proclara Biosciences, Inc. | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity |
| EA201791212A1 (ru) | 2014-12-03 | 2018-01-31 | Проклара Байосайенсиз, Инк. | Полипептиды, содержащие аминокислотную последовательность модифицированного бактериофага g3p, в которой отсутствует сигнал гликозилирования |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2344189T3 (es) * | 1999-09-03 | 2010-08-20 | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. | Agentes, composiciones y metodos que los utilizan utiles en el tratamiento o la prevencion de la enfermedad de alzheimer. |
| AU2002223886A1 (en) * | 2000-11-24 | 2002-06-03 | Isis Innovation Limited | Mixed fibrils |
| ES2392247T3 (es) * | 2002-03-05 | 2012-12-07 | Ramot At Tel-Aviv University Ltd. | Compuesto inmunizante y método para inducir una respuesta inmune contra el sitio de escisión de la beta-secretasa de la proteína precursora de amiloide |
| GB0305918D0 (en) * | 2003-03-14 | 2003-04-23 | Glaxo Group Ltd | Novel compounds |
| FR2855178B1 (fr) * | 2003-05-20 | 2005-08-05 | Centre Nat Rech Scient | Peptides modulateurs de l'activite du facteur de transcription engrailed |
| EP1853299A4 (en) * | 2005-01-14 | 2009-11-11 | Univ California | COMPOSITIONS AND METHODS FOR INHIBITING THE PRESENCE OF DRUGS AND DIAGNOSING OR TREATING DRUG-INDUCED DISEASES |
| ES2363203T3 (es) * | 2005-02-01 | 2011-07-26 | Ramot At Tel-Aviv University Ltd. | Método para tratar una inflamación asociada a depósitos amiloides y una inflamación cerebral que implica una microglia activada. |
| BRPI0707871A2 (pt) * | 2006-02-15 | 2011-05-10 | Ramot At Tel Aviv University | veÍculos de exibiÇço de fago, composiÇço farmacÊutica ,e, mÉtodos para o tratamento ou a inbiÇço e para o diagnàsticos de uma doenÇa, distébio ou condiÇço cerebral |
| CA2659032A1 (en) * | 2006-07-21 | 2008-01-24 | Ramot At Tel Aviv University Ltd. | Method for inhibiting or treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates |
| WO2009143470A1 (en) * | 2008-05-22 | 2009-11-26 | Ramot At Tel Aviv University Ltd. | Method for treating disease characterized by plaque |
-
2009
- 2009-11-24 SG SG2011037066A patent/SG171791A1/en unknown
- 2009-11-24 KR KR1020117014511A patent/KR20110091778A/ko not_active Withdrawn
- 2009-11-24 EP EP12151176A patent/EP2478911A1/en not_active Withdrawn
- 2009-11-24 AU AU2009316326A patent/AU2009316326A1/en not_active Abandoned
- 2009-11-24 CN CN2009801467441A patent/CN102223887B/zh not_active Expired - Fee Related
- 2009-11-24 RU RU2011125971/15A patent/RU2011125971A/ru not_active Application Discontinuation
- 2009-11-24 CA CA2744339A patent/CA2744339A1/en active Pending
- 2009-11-24 US US13/130,894 patent/US20110286970A1/en not_active Abandoned
- 2009-11-24 NZ NZ592928A patent/NZ592928A/xx not_active IP Right Cessation
- 2009-11-24 BR BRPI0921557A patent/BRPI0921557A2/pt not_active IP Right Cessation
- 2009-11-24 JP JP2011537703A patent/JP2012509672A/ja active Pending
- 2009-11-24 MX MX2011005430A patent/MX2011005430A/es not_active Application Discontinuation
- 2009-11-24 WO PCT/US2009/065659 patent/WO2010060073A2/en not_active Ceased
- 2009-11-24 EP EP09775018A patent/EP2358377A2/en not_active Withdrawn
-
2011
- 2011-05-24 IL IL213120A patent/IL213120A0/en unknown
- 2011-06-23 CO CO11078816A patent/CO6390112A2/es not_active Application Discontinuation
- 2011-06-24 ZA ZA2011/04701A patent/ZA201104701B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012509672A (ja) | 2012-04-26 |
| US20110286970A1 (en) | 2011-11-24 |
| ZA201104701B (en) | 2012-09-26 |
| KR20110091778A (ko) | 2011-08-12 |
| WO2010060073A3 (en) | 2010-09-02 |
| AU2009316326A1 (en) | 2010-05-27 |
| BRPI0921557A2 (pt) | 2019-09-24 |
| NZ592928A (en) | 2012-12-21 |
| SG171791A1 (en) | 2011-07-28 |
| IL213120A0 (en) | 2011-07-31 |
| CO6390112A2 (es) | 2012-02-29 |
| WO2010060073A2 (en) | 2010-05-27 |
| EP2358377A2 (en) | 2011-08-24 |
| CA2744339A1 (en) | 2010-05-27 |
| HK1162964A1 (en) | 2012-09-07 |
| CN102223887B (zh) | 2013-11-06 |
| EP2478911A1 (en) | 2012-07-25 |
| MX2011005430A (es) | 2011-10-28 |
| CN102223887A (zh) | 2011-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025166059A (ja) | Ｔ制御性細胞の増殖または枯渇方法 | |
| WO2019128952A1 (zh) | 携带嵌合抗原受体的免疫细胞外泌体的制备方法及其应用 | |
| RU2008129827A (ru) | МОЛЕКУЛЫ EphA2-BiTE И ИХ ПРИМЕНЕНИЕ | |
| US20150023972A1 (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| RU2016130447A (ru) | Гетеродимерный белок il-15 и его применения | |
| RU2535034C2 (ru) | Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида | |
| JPH029394A (ja) | ヒトインターフエロンベーター２、その精製法及びその用途 | |
| PE20021151A1 (es) | Uso de anticuerpos anti-tnf como farmacos en el tratamiento de trastornos septicos de racientes anemicos | |
| RU2012133522A (ru) | Новое применение соединений ил-1 бета | |
| RU2011153016A (ru) | Три- или тетраспецифические антитела | |
| JP2012504602A5 (enExample) | ||
| RU2535033C2 (ru) | Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида | |
| Finkelman et al. | Production of BSF-1 during an in vivo, T-dependent immune response. | |
| CN106749594B (zh) | 包含f1、f3多肽的药物组合物及其在治疗hpv感染疾病中的应用 | |
| CA2744339A1 (en) | Method for treating parkinson's disease | |
| JP6929928B2 (ja) | Ｈｌａ−ｇ特異的キメラ抗原受容体、核酸、ｈｌａ−ｇ特異的キメラ抗原受容体発現プラスミド、ｈｌａ−ｇ特異的キメラ抗原受容体発現細胞及び癌治療用の医薬組成物 | |
| CN117771365B (zh) | 一种抗狂犬病病毒组合单克隆抗体制剂 | |
| JP2022513331A5 (enExample) | ||
| CN113354731B (zh) | 冠状病毒的人源单克隆抗体及其应用 | |
| JP2013535483A (ja) | Ｐ２４タンパク質の産生を阻害するか又は排出を促進する医薬組成物及び方法 | |
| CN118240093A (zh) | 一种靶向her2与egfr的三特异性t细胞衔接器及其应用 | |
| KR960002183B1 (ko) | 호산구증다증 억제또는 경감을 위한 약제학적 조성물 | |
| Kishimoto et al. | Immunoglobulin treatment ameliorates murine myocarditis associated with reduction of neurohumoral activity and improvement of extracellular matrix change | |
| JP2017525752A (ja) | 静注用免疫グロブリンの精製組成物及びリンパ球を調整しｂ型肝炎を治療するためのｋｈタンパク質 | |
| WO2023046097A1 (zh) | 抗tigit人源化抗体或其抗原结合片段及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20140611 |